The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported ...
In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback